These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27111901)

  • 1. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Therapies in Prostate Cancer.
    Goswami S; Aparicio A; Subudhi SK
    Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Therapy in Head and Neck Cancers.
    Msaouel P; Massarelli E
    Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint Immunotherapy: Picking a Winner.
    Teng MW; Khanna R; Smyth MJ
    Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
    El Rassy E; Assi T; Kattan J
    Future Oncol; 2017 Feb; 13(5):381-383. PubMed ID: 27884060
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The science of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are virus-induced cancers more sensitive to checkpoint inhibitors?
    Kanaan H; Kourie HR; Awada AH
    Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical use of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor and T-cell metabolism: new insights into melanoma therapy.
    Delgoffe GM
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):232-4. PubMed ID: 27166604
    [No Abstract]   [Full Text] [Related]  

  • 17. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
    Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
    Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.